Shares of Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) ended Friday session in red amid volatile trading. The shares closed down -0.09 points or -3.75% at $2.31 with 45,439 shares getting traded. Post opening the session at $2.38, the shares hit an intraday low of $2.30 and an intraday high of $2.45 and the price vacillated in this range throughout the day.

Market Cap/Outstanding Shares

The company has a market cap of $29.47 million and the number of outstanding shares have been calculated to be 13.25 million shares.

Performance weekly/monthly/quarterly/yearly in percentage (%)

The performance for the week is valued at -13.16%, resulting in a performance for the month at -24.26%. Therefore, the stated figure displays a quarterly performance of -37.74% and an annual performance of -54.79%.traded up -3.75% on 18 November, 2016 hitting $2.31.

EPS (Earning Per Share )

The EPS of IMMY is strolling at -1.59, measuring its EPS growth this year at -49.90%. Company’s EPS for the past five years is valued at 15.00%, leading it to an EPS value of 23.70% for the next five years.


Imprimis Pharmaceuticals Inc has a P/S value of 1.80, measuring P/B at 11.00. Its P/Cash is valued at 10.97.


Beta factor is stands at 0.47 and Avg. true range is 0.29. Historically, the volatility of this stock is about 10.73% a week and 10.98% a month.

Imprimis Pharmaceuticals Inc (IMMY) recently declared it has reached a product purchase and supply agreement with the specialty pharmacy division of one of the nation’s leading pharmacy benefit managers (PBMs) to supply Imprimis’ complete formulary of low-cost compounded medications through the PBM’s national network of specialty pharmacies.  Under the agreement:

The Imprimis Cares® formulary will be made available through the specialty pharmacy division of the PBM, which includes more than 65 million covered lives.

Imprimis will supply all formulations included under its Imprimis Cares® formulary counting the patent-pending tiopronin delayed-release formulations, a lower cost alternative to Thiola®; pyrimethamine and leucovorin formulations, an alternative to Daraprim®; the company’s proprietary Dropless Therapy® injectable and LessDrops® topical formulations; in addition to additional compounded drug formulations for patient populations that may not have available alternatives to increasingly expensive branded medications and lacking meaningful generic competition.

Prescription orders will flow through Imprimis’ MaxRx Prescriber Portal™, allowing for customer ordering and tracking ease.

Both parties shall ensure that patients continue to receive expert personalized support needed to manage their specific conditions.



Please enter your comment!
Please enter your name here